Keywords: adenocarcinoma; ALK; EGFR; molecular pathology; non-small cell lung cancer; pathology; PD-L1; ROS1;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: NSCLC; ROS1; RET; NTRK; MET; BRAF; KRAS; Driver mutations;
Keywords: Del; Delila; F3â²5â²H; flavonoid 3â²5â²-hydroxylas; PAL; phenylalanine ammonia-lyase; Ros1; Rosea1; Anthocyanins; Transgenic tomatoes; Delila; Rosea1;
Keywords: Anaplastic lymphoma kinase (ALK); Driver oncogene; Epidermal growth factor receptor (EGFR); KRAS; Non–small-cell lung cancer; NRAS; Pemetrexed; ROS1
Keywords: Non-small-cell lung cancer; Next generation sequencing; Genotype; EGFR; ALK; Driver oncogene; MET; ROS1; MET; Adenocarcinoma; Squamous cell carcinomas;
Keywords: Biomarkers; Lung cancer; NSCLC; EGFR; ALK; ROS1; RET
Keywords: FGFR2; HER2; ERBB2; ROS1; Tyrosine kinase; Targeted therapy; Bile;
Keywords: EGFR mutation; KRAS mutation; ROS1; Non-small cell lung cancer
Keywords: Lung; Pulmonary; Adenocarcinoma; ALK; ROS1; Pediatric patients
Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry
Keywords: ALK; anaplastic lymphoma kinase; EMA; European Medicines Agency; EML4; echinoderm microtubule-associated protein-like 4; ESI; electro spray ionization; FDA; Food and Drug Administration; IS; internal standard; LC-MS/MS; liquid chromatography-tandem mass s
3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer
Keywords: 3D culture system; ROS1; TKI; HCC78; NSCLC;
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Keywords: ALK; anaplastic lymphoma kinase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; cMET; tyrosine-protein kinase Met/hepatocyte growth factor receptor; CT; computer tomography; ECOG; PS Eastern Cooperative Oncology Group performance status; EGFR; epide
Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
Keywords: ROS1; molecular testing; next-generation sequencing; FISH; lung cancer;
ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses
Keywords: Thrombosis; Venous thromboembolic event; ROS1;
Exosomes as a liquid biopsy for lung cancer
Keywords: Alix; ALG 2 interacting protein X; ALK; anaplastic lymphoma kinase; AREG; Amphiregulin; Atg2; autophagy related protein 2; AUC; area under the curve; BAL; bronchoalveolar lavage; circRNA; circular RNA; CSE; cigarette smoke extract; CTC; circulating tumor
Functional analyses of PtRDM1 gene overexpression in poplars and evaluation of its effect on DNA methylation and response to salt stress
Keywords: PtRDM1; PtROS1; DNA methylation; Salt stress; Poplar; RDM1; RNA-directed DNA methylation 1; ROS1; Repressor of Silencing; qPCR; quantitative Polymerase Chain Reaction; RdDM; RNA-directed DNA methylation;
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Keywords: ROS1; Crizotinib; Pemetrexed; Carcinoma; Non-small cell lung cancer;
Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation
Keywords: Crizotinib; DIC; Intensive care; NSCLC; ROS1;
Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung
Keywords: Serum tumor marker; CEA; CA125; CA199; CA2729; Non-small cell lung cancer; EGFR; KRAS; ROS1; ALK;
Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer
Keywords: ALK; Immunohistochemistry; Multiplex FISH; NSCLC; ROS1;
Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R
Keywords: 2,4-Diarylaminopyrimidine; Dual inhibitor; ALK; ROS1; Crizotinib-resistant;
Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer
Keywords: ALK; ROS1; Fluorescent in situ hybridization; Non-small-cell lung cancer;
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study
Keywords: ALK; Anaplastic Lymphoma Kinase; BMI; body mass index; CCI; Charlson Comorbidity Index; CI; confidence interval; CR; complete response; CRISP; clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patien
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer
Keywords: ROS1; Non-small cell lung cancer; NSCLC; Concurrent mutations;
A point mutation in the heavy chain complementarity-determining region 3 (HCDR3) significantly enhances the specificity of an anti-ROS1 antibody
Keywords: ROS1; Antibody; Specificity; Mutation; Epitope; mAbs; monoclonal antibodies; ELISA; enzyme-linked immunosorbent assay; Fc; fragment crystallizable; CK; kappa light chain constant region; HRP; horseradish peroxidase; IHC; Immunohistochemistry;
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
Keywords: Lung adenocarcinoma; ROS1; Concomitant mutations; EGFR; Pemetrexed;
Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance
Keywords: Acquired resistance; ALK; Clinical trial; Crizotinib; EGFR; MET exon 14; Neoadjuvant treatment; NSCLC; ROS1;
Stratégie de testing moléculaire des carcinomes pulmonaires
Keywords: Cancer du poumon; EGFR; ALK; KRAS; ROS1; Algorithme de test; Biopsie; Lung cancer; EGFR; ALK; KRAS; ROS1; Algorithm of testing; Biopsy;
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
Keywords: ROS1; KIT; NSCLC; Drug resistance; Tyrosine kinase inhibitor; Bypass signaling;
Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1
Keywords: 4-Arylaminopyrimidine derivatives; Hydrazone moiety; Dual inhibitor; L1196M ALK; ROS1;
Ciblage de MET, T790M et ROS1
Keywords: ROS1; Met; Cancer bronchique; Traitements ciblés; ROSI; Met; Lung cancer; Targeted therapy;
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
Keywords: Mutation; Lung cancer; Adenocarcinoma; MET; Exon 14; Amplification; PIK3CA; ALK; ROS1; Crizotinib; Ceritinib;
A Mass Spectrometry Assay to Simultaneously Analyze ROS1 and RET Fusion Gene Expression in Non-Small-Cell Lung Cancer
Keywords: Fusion gene; Non-small-cell lung cancer; Mass spectrometry; ROS1; RET;
ROS1 Immunohistochemistry Among Major Genotypes of Non-Small-Cell Lung Cancer
Keywords: Adenocarcinoma; Biomarker; Gene rearrangement; NSCLC; ROS1;
Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival
Keywords: Lung cancer; ROS1; Immunohistochemistry; Histomorphology;
Expression and function of AtMBD4L, the single gene encoding the nuclear DNA glycosylase MBD4L in Arabidopsis
Keywords: BER; base excision repair; DME; DEMETER; FPG; formamidopyrimidine DNA glycosylase; HhH; helix-hairpin-helix; MBD4; methyl-binding domain protein 4; MPG; 3-methyl-purine glycosylase; MutY; A/G-mismatch-specific adenine glycosylase; NEI; endonuclease VIII-l
Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer
Keywords: ALK; ROS1; Non-small-cell lung cancer; Fluorescence in situ hybridization; Immunohistochemistry; Chromogenic in situ hybridization;
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor
Keywords: Lung cancer; EGFR; KRAS; ALK; HER2; BRAF; MET; ROS1; RIT1; TTF-1 lung adenocarcinoma; NRAS; Driver mutations; Oncogenic driver mutation; East Asian lung cancer; MET amplification; Targeted therapy; Genetic marker; Biomarker; Molecular classification lung
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
Keywords: Non-small cell lung cancer; Oncogenic drivers; EGFR; ALK; KRA; BRAF; HER2; PI3KCA; DDR2; ROS1
Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing
Keywords: Non-small cell lung cancer; MET; ALK; ROS1; FISH; IHC; Targeted therapy; Predictive biomarkers;
Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series
Keywords: Crizotinib; FISH; IHC; NSCLC; ROS1;
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma
Keywords: Anaplastic lymphoma kinase; Prevalence; Epidermal growth factor receptor; Prognosis; Characteristic; Non-small cell lung cancer; ROS1;
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas
Keywords: ROS1; c-ros oncogene-1; ALK; anaplastic lymphoma kinase; EGFR; epidermal growth factor receptor; KRAS; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; FISH; fluorescent in situ hybridization; IHC; immunohistochemistry; ROS1; FISH; Immunohistochemist
Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors
Keywords: Cancer; Kinase inhibitor; NSCLC; ROS1; Structure–activity relationship; Suzuki coupling
A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements
Keywords: Chemotherapy; Molecular subtypes; NSCLC; Pemetrexed; ROS1;
Crizotinib in the Treatment of Non-Small-Cell Lung Cancer
Keywords: Anaplastic lymphoma kinase; EML4-ALK; ROS1; Targeted therapy; Tyrosine kinase inhibitor;
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia
Keywords: ROS1; CMML; Chronic myeloproliferative neoplasms; Proliferation; Tyrosine kinase; Molecular target;
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm
Keywords: Pulmonary adenocarcinoma; ROS1; Fluorescence in situ hybridization; Clinicopathology; Molecular enrichment strategy
Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
Keywords: Lung cancer; Non–small-cell lung cancer; Tyrosine kinase; Kinase inhibitor; Epidermal growth factor receptor; Anaplastic lymphoma kinase; ALK; ROS1; Crizotinib
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
Keywords: Non–-small-cell lung cancer; Targeted therapy; ROS1; Anaplastic lymphoma kinase inhibitors; Crizotinib